Figure 4.
Progression-free survival of patients treated with CIMAvax-EGF. Progression-free survival rates at 6, 12, and 24 months were 55.4%, 36.4%, and 19.1%, respectively.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.